474 related articles for article (PubMed ID: 23172872)
1. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility.
Theodorou V; Stark R; Menon S; Carroll JS
Genome Res; 2013 Jan; 23(1):12-22. PubMed ID: 23172872
[TBL] [Abstract][Full Text] [Related]
2. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
[TBL] [Abstract][Full Text] [Related]
3. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
[TBL] [Abstract][Full Text] [Related]
4. Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover.
Adomas AB; Grimm SA; Malone C; Takaku M; Sims JK; Wade PA
BMC Cancer; 2014 Apr; 14():278. PubMed ID: 24758297
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.
Joosten SEP; Gregoricchio S; Stelloo S; Yapıcı E; Huang CF; Yavuz K; Donaldson Collier M; Morova T; Altintaş UB; Kim Y; Canisius S; Moelans CB; van Diest PJ; Korkmaz G; Lack NA; Vermeulen M; Linn SC; Zwart W
Genome Res; 2024 May; 34(4):539-555. PubMed ID: 38719469
[TBL] [Abstract][Full Text] [Related]
6. Establishment of active chromatin structure at enhancer elements by mixed-lineage leukemia 1 to initiate estrogen-dependent gene expression.
Jeong KW; Andreu-Vieyra C; You JS; Jones PA; Stallcup MR
Nucleic Acids Res; 2014 Feb; 42(4):2245-56. PubMed ID: 24288367
[TBL] [Abstract][Full Text] [Related]
7. Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.
Kong SL; Li G; Loh SL; Sung WK; Liu ET
Mol Syst Biol; 2011 Aug; 7():526. PubMed ID: 21878914
[TBL] [Abstract][Full Text] [Related]
8. Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium.
Fishwick C; Higgins J; Percival-Alwyn L; Hustler A; Pearson J; Bastkowski S; Moxon S; Swarbreck D; Greenman CD; Southgate J
Cell Death Differ; 2017 May; 24(5):809-818. PubMed ID: 28282036
[TBL] [Abstract][Full Text] [Related]
9. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
[TBL] [Abstract][Full Text] [Related]
10. Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer.
Dreijerink KMA; Groner AC; Vos ESM; Font-Tello A; Gu L; Chi D; Reyes J; Cook J; Lim E; Lin CY; de Laat W; Rao PK; Long HW; Brown M
Cell Rep; 2017 Mar; 18(10):2359-2372. PubMed ID: 28273452
[TBL] [Abstract][Full Text] [Related]
11. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.
Lupien M; Eeckhoute J; Meyer CA; Wang Q; Zhang Y; Li W; Carroll JS; Liu XS; Brown M
Cell; 2008 Mar; 132(6):958-70. PubMed ID: 18358809
[TBL] [Abstract][Full Text] [Related]
12. FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1-Mutant Breast Cancer.
Wu Y; Li Z; Wedn AM; Casey AN; Brown D; Rao SV; Omarjee S; Hooda J; Carroll JS; Gertz J; Atkinson JM; Lee AV; Oesterreich S
Mol Cancer Res; 2023 Jun; 21(6):591-604. PubMed ID: 36930833
[TBL] [Abstract][Full Text] [Related]
13. NR2F2 Orphan Nuclear Receptor is Involved in Estrogen Receptor Alpha-Mediated Transcriptional Regulation in Luminal A Breast Cancer Cells.
Erdős E; Bálint BL
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168782
[TBL] [Abstract][Full Text] [Related]
14. TET2 is a component of the estrogen receptor complex and controls 5mC to 5hmC conversion at estrogen receptor cis-regulatory regions.
Broome R; Chernukhin I; Jamieson S; Kishore K; Papachristou EK; Mao SQ; Tejedo CG; Mahtey A; Theodorou V; Groen AJ; D'Santos C; Balasubramanian S; Farcas AM; Siersbæk R; Carroll JS
Cell Rep; 2021 Feb; 34(8):108776. PubMed ID: 33626359
[TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-α gene.
Powers GL; Rajbhandari P; Solodin NM; Bickford B; Alarid ET
PLoS One; 2013; 8(12):e81110. PubMed ID: 24339902
[TBL] [Abstract][Full Text] [Related]
16. A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.
Lee JY; Park YJ; Oh N; Kwack KB; Park KS
Oncotarget; 2017 Jun; 8(26):42752-42760. PubMed ID: 28514748
[TBL] [Abstract][Full Text] [Related]
17. Enhancer activation requires trans-recruitment of a mega transcription factor complex.
Liu Z; Merkurjev D; Yang F; Li W; Oh S; Friedman MJ; Song X; Zhang F; Ma Q; Ohgi KA; Krones A; Rosenfeld MG
Cell; 2014 Oct; 159(2):358-73. PubMed ID: 25303530
[TBL] [Abstract][Full Text] [Related]
18. Absent, small or homeotic 2-like protein (ASH2L) enhances the transcription of the estrogen receptor α gene through GATA-binding protein 3 (GATA3).
Qi J; Huo L; Zhu YT; Zhu YJ
J Biol Chem; 2014 Nov; 289(45):31373-81. PubMed ID: 25258321
[TBL] [Abstract][Full Text] [Related]
19. Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression.
Chen D; Parker TM; Bhat-Nakshatri P; Chu X; Liu Y; Wang Y; Nakshatri H
Oncogene; 2021 Feb; 40(7):1332-1346. PubMed ID: 33420376
[TBL] [Abstract][Full Text] [Related]
20. About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer.
Lacroix M; Leclercq G
Mol Cell Endocrinol; 2004 Apr; 219(1-2):1-7. PubMed ID: 15149721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]